Ideally, molecular testing would be able to assess for relevant copy number alterations and chromosomal arm changes (gain of chromosome 7, loss of chromosome 10, EGFR amplification), along with other relevant mutations in “non-GBM” IDH-wildtype tumors (TERT promoter, BRAFV600E, MYCN, MMR, EGFR, PDGFRA, p53). This evidence concerns the gene IDH2 and glioblastoma.